Truist Securities Maintains Buy on Beta Bionics, Raises Price Target to $28

Truist Securities analyst Richard Newitter has maintained a 'Buy' rating on Beta Bionics (NASDAQ: BBNX) and raised the price target from $23 to $28. This adjustment reflects a positive outlook for the company's stock performance.